It is a Phase II trial for recurrent endometrial or ovarian cancer with ANY “endometriod” histology including mixed or carcinosarcoma as long as a portion of it had “endometriod” histology. DKN-01 (an inhibitor of DKK1, which modulates both the canonical and noncanonical Wnt signaling pathway) +/- weekly Paclitaxel. DKK1 is thought to promote immune evasion, so blocking it activates the immune system to fight the cancer.
Here is the link for more information:
Dr. Rebecca Arend is the national Principle Investigator for the study. For further information or consultation to determination whether you meet the criteria to join the study you may contact Dr. Arend’s office at 205-996-4662.
Alternatively, you can go to providerdirectory.uabmedicine.org, type in Dr. Rebecca Arend’s name and fill out an appointment form on line.
The GCS Project Team
Clinical trials are currently being offered at the University of Arkansas for Medical Sciences (UAMS). Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single… Read More »
Clinical trials are currently being offered at the University of Alabama at Birmingham. Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in… Read More »
Clinical trials are currently being offered at Medical University of South Carolina (MUSC) Health Care in Charleston SC. A Phase II/III Study of Paciltaxel/Carboplatin alone, or combined with either Trastuzumab… Read More »